This article is more than 5 years old. Information may no longer be current.
European Commission approves Humira for treatment of chronic plaque psoriasis in children
Click Here to Manage Email Alerts
AbbVie announced that Humira has received marketing authorization from the European Commission for the treatment of severe chronic plaque psoriasis in children and adolescents ages 4 years and older who do not respond to topical therapy or phototherapies.
The European Commission action, based on phase 3 study results, approved Humira (adalimumab) for this indication in all member states of the European Union, according to a press release. The study results will be presented at an upcoming medical meeting, Abbvie reported.
“With the approval from the European Commission, Humira is now the only biologic approved in Europe to treat children with this condition starting at 4 years of age, offering an important new option for physicians treating pediatric plaque psoriasis,” Michael Severino, MD, executive vice president of research and development and chief scientific officer for AbbVie, said in the release.
Adalimumab is currently approved in more than 87 countries for 11 globally approved indications, according to the release.
Reference: www.abbvie.com.